SSII
SS Innovations International Inc. Common StockSSII
SSII
About: SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.
Employees: 378
–
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for SSII.
Financial journalist opinion
Based on 3 articles about SSII published over the past 30 days
Neutral
MCAP MediaWire
1 week ago
SS Innovations to Ring the Nasdaq Opening Bell on Tuesday, June 3, 2025
Fort Lauderdale, FL, June 2, 2025 – PRISM MediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company will ring the opening bell at the Nasdaq MarketSite in New York City on Tuesday, June 3, 2025. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, will lead the bell ringing ceremony and be joined by members of the Company's management team, Board of Directors, advisors, and other guests.
Neutral
MCAP MediaWire
2 weeks ago
SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
FORT LAUDERDALE, Fla., May 27, 2025 – PRISM MediaWire – SS Innovations International, Inc.
Neutral
GlobeNewsWire
2 weeks ago
SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company's SSi Mantra surgical robotic system has been utilized to successfully perform more than 4,000 robotic surgeries across more than one hundred types of surgeries without any complications, injuries or mortalities.
Neutral
MCAP MediaWire
1 month ago
SS Innovations Reports First Quarter 2025 Financial Results
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 Fort Lauderdale, FL, May 14, 2025 – PRISM MediaWire – SS Innovations International, Inc.
Neutral
GlobeNewsWire
1 month ago
SS Innovations Reports First Quarter 2025 Financial Results
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025.
Neutral
MCAP MediaWire
1 month ago
SS Innovations to Submit De Novo Application to the FDA for the SSi Mantra 3 Surgical Robotic System for Multiple Indications
All Clinical Data Validated by Leading Third-Party CRO for Safety, Feasibility and Efficacy FORT LAUDERDALE, Fla., May 08, 2025 – PRISM MediaWire – SS Innovations International, Inc.
Neutral
GlobeNewsWire
1 month ago
SS Innovations to Submit De Novo Application to the FDA for the SSi Mantra 3 Surgical Robotic System for Multiple Indications
FORT LAUDERDALE, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company is planning to submit a De Novo Classification Request to the U.S. Food and Drug Administration (the “FDA”) for the SSi Mantra 3 surgical robotic system (the “SSi Mantra 3”) in July 2025.
Neutral
MCAP MediaWire
1 month ago
SS Innovations Reiterates Guidance for First Quarter 2025 and Provides Commentary on Second Quarter 2025 Order Trends
Press Audio Overview: FORT LAUDERDALE, Fla., May 05, 2025 – PRISM MediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
SS Innovations Reiterates Guidance for First Quarter 2025 and Provides Commentary on Second Quarter 2025 Order Trends
FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
SS Innovations Announces Chief Financial Officer Transition
FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company's Interim Chief Financial Officer, effective May 1, 2025, pursuant to a planned leadership transition.
Charts implemented using Lightweight Charts™